Surgery or radiation, not monitoring, most often sought for low-risk prostate cancer, Mayo finds

Study is among Mayo research presented at North Central American Urological Association Meeting

2012-10-12

(Press-News.org) ROCHESTER, Minn. -- Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study being presented at the North Central Section of the American Urological Association's annual meeting Oct. 10 in Chicago. Mayo Clinic urologists also are discussing findings on enlarged prostates, bladder cancer and other research and will be available to provide expert comment to journalists on others' studies.

Mayo studies being presented, and their embargo dates and times, include:

Active Surveillance for Low-risk Prostate Cancer Recommended Least Often by Physicians
Embargoed until Friday, Oct. 12, 2012, noon ET.

While active surveillance is widely regarded as an effective strategy for managing low-risk prostate cancer, a Mayo Clinic study of 643 urologists and radiation oncologists found that only 21 percent of physicians studied recommended the strategy while 47 percent recommended surgery and 32 percent recommended radiation therapy.

Overall, physician recommendations aligned with their area of expertise. Most urologists recommended surgery, and most radiation oncologists recommended radiation therapy.

"Our results may explain in part the relatively low use of active surveillance for low-risk prostate cancer in the United States," says lead author Simon Kim, M.D., M.P.H., a urologic oncologist at Mayo Clinic.

Laser Surgery Relieves Symptoms After Unsuccessful Surgery for Enlarged Prostate
Embargoed until Tuesday, Oct. 9, 2012, 10:30 a.m. ET.

Holmium laser prostate surgery is safe and effective at relieving persistent lower urinary tract symptoms after an unsuccessful surgery to treat an enlarged prostate, a Mayo Clinic study has found. The laser surgery reduces the size of the prostate gland or increases the size of the channel through which urine flows.

The study compared surgical and postsurgical outcomes among patients who had a previous unsuccessful surgery for enlarged prostate and a group with no previous surgery.

"Other than a slower morcellation rate — the rate at which the laser removes tissue — and a slower average urine flow rate for patients who had a previous surgery, the study found no significant difference in outcomes between the groups," says urologist Amy Krambeck, M.D., the study's senior author.

Half of Urothelial Cancer Patients Who Get Surgery Aren't Cisplatin Chemotherapy Candidates
Embargoed until Friday, Oct. 12, 2012, 11:50 a.m. ET.

Nearly 50 percent of urothelial cancer patients receiving a radical cystectomy are not eligible to receive cisplatin-based chemotherapy before surgery, based on their kidney function alone, a Mayo Clinic study shows. Urothelial cancer is the most common form of bladder cancer in the United States.

The study also found that nearly one in five patients who were candidates for cisplatin-based chemotherapy before surgery were no longer eligible for it after surgery. Older patients and patients undergoing a continent urinary diversion, such as a neobladder, were more likely to have reduced kidney function after surgery.

The study included 741 patients with urothelial cancer who had a radical cystectomy at Mayo Clinic between 1980 and 2005. "This study highlights the fact that many patients who need a cystectomy for bladder cancer are not great candidates for cisplatin-based chemotherapy, both before and after surgery," says lead author R. Houston Thompson, M.D., a Mayo urologist. "It also is notable that after surgery some patients become ineligible for cisplatin-based chemotherapy, and this should be kept in mind as doctors counsel patients.

### About Mayo Clinic Cancer Center As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

About Mayo Clinic Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.

ELSE PRESS RELEASES FROM THIS DATE:

Scientists discover that shape matters in DNA nanoparticle therapy

2012-10-12

Researchers from Johns Hopkins and Northwestern universities have discovered how to control the shape of nanoparticles that move DNA through the body and have shown that the shapes of these carriers may make a big difference in how well they work in treating cancer and other diseases. This study, to be published in the Oct. 12 online edition of the journal Advanced Materials, is also noteworthy because this gene therapy technique does not use a virus to carry DNA into cells. Some gene therapy efforts that rely on viruses have posed health risks. "These nanoparticles ...

Report -- illegal hunting and trade of wildlife in savanna Africa may cause conservation crisis

2012-10-12

New York, NY and Hyderabad (India) – A new report published today by Panthera confirms that widespread illegal hunting and the bushmeat trade occur more frequently and with greater impact on wildlife populations in the Southern and Eastern savannas of Africa than previously thought, and if unaddressed could potentially cause a 'conservation crisis.' The report challenges previously held beliefs of the impact of illegal bushmeat hunting and trade in Africa with new data from experts. While the bushmeat trade has long been recognized as a severe threat to the food resources ...

New weapons detail reveals true depth of Cuban Missile Crisis

2012-10-12

The Cuban Missile Crisis took place 50 years ago this October, when US and Soviet leaders pulled back from the very brink of nuclear war. This was the closest the world has come to nuclear war, but exactly how close has been a matter of some speculation. The conflict, itself, has been analyzed and interpreted, but the number and types of nuclear weapons that were operational have not. According to fresh analysis available today in the Bulletin of the Atomic Scientists, published by SAGE, senior experts calculate the nature of weapons capabilities on both sides, and write ...

GMES for Europe

2012-10-12

The potential of GMES for crisis management and environmental monitoring is highlighted in a new publication with users demonstrating the importance of Earth observation data to European regions. The joint ESA-NEREUS (Network of European Regions Using Space Technologies) publication is a collection of articles that provide insight into how the Global Monitoring for Environment and Security (GMES) programme is being used in new applications and services across Europe. The articles, prepared by regional end-users, research institutes and industry providers from 17 different ...

Development of 2 tests for rapid diagnosis of resistance to antibiotics

2012-10-12

With their excellent sensitivity and specificity, the use of these extremely efficient tests on a world-wide scale would allow us to adapt antibiotic treatments to the individual's needs and to be more successful in controlling antibiotic resistance, particularly in hospitals. These works were published in September in two international reviews: Emerging Infectious diseases and The Journal of Clinical Microbiology. These diagnostic tests will allow rapid identification of certain bacteria that are resistant to antibiotics and hence: Allow us to better adapt the treatment ...

Scientists identify trigger for explosive volcanic eruptions

2012-10-12

Scientists from the University of Southampton have identified a repeating trigger for the largest explosive volcanic eruptions on Earth. The Las Cañadas volcanic caldera on Tenerife, in the Canary Islands, has generated at least eight major eruptions during the last 700,000 years. These catastrophic events have resulted in eruption columns of over 25km high and expelled widespread pyroclastic material over 130km. By comparison, even the smallest of these eruptions expelled over 25 times more material than the 2010 eruption of Eyjafjallajökull, Iceland. By analysing ...

The body's own recycling system

2012-10-12

Almost everything that happens inside a cell, including autophagy, is tightly regulated on a biochemical level. Like that, the cell makes sure that processes only take place when they are needed and that they are shut off when the need has expired. "Inside the cell, there exists a network of molecules. Between them, information is constantly being exchanged," says Schmitz, head of the research group "Systems-oriented Immunology and Inflammation Research" at HZI, who also holds a chair at the Otto von Guericke University in Magdeburg. "In a way, it looks like a big city ...

The worst noises in the world: Why we recoil at unpleasant sounds

2012-10-12

In a study published in the Journal of Neuroscience and funded by the Wellcome Trust, Newcastle University scientists reveal the interaction between the region of the brain that processes sound, the auditory cortex, and the amygdala, which is active in the processing of negative emotions when we hear unpleasant sounds. Brain imaging has shown that when we hear an unpleasant noise the amygdala modulates the response of the auditory cortex heightening activity and provoking our negative reaction. "It appears there is something very primitive kicking in," says Dr Sukhbinder ...

Kidney grafts function longer in Europe than in the United States

2012-10-12

Kidney transplants performed in Europe are considerably more successful in the long run than those performed in the United States. While the one-year survival rate is 90% in both Europe and the United States, after five years, 77% of the donor kidneys in Europe still function, while in the United States, this rate among white Americans is only 71%. After ten years, graft survival for the two groups is 56% versus 46%, respectively. The lower survival rates compared to Europe also apply to Hispanic Americans, in whom 48% of the transplanted kidneys still function after ten ...

Neuroscientists from Louisiana Tech University to present at international conference

2012-10-12

RUSTON, La. – Dr. Mark DeCoster, the James E. Wyche III Endowed Professor in Biomedical Engineering at Louisiana Tech University, will lead a team of Louisiana Tech neuroscientists in presenting a lecture at the Society for Neuroscience's (SfN) annual meeting, October 15 in New Orleans. The lecture titled, "Randomization of submaximal glutamate stimulus to interpret astrocyte effect on calcium dynamics," will be featured as part of Neuroscience 2012 – SfN's annual meeting that provides the world's largest forum for neuroscientists to debut research and network with colleagues ...